Mirae Asset Global ETFs Holdings
YMAB

Mirae Asset Global ETFs Holdings’s Y-mAbs Therapeutics YMAB Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-21,185
Closed -$95.5K – 3161
2025
Q2 		$95.5K Sell
21,185
-936
-4% -$4.21K ﹤0.01% 2631
2025
Q1 		$98K Sell
22,121
-697
-3% -$4.05K ﹤0.01% 2639
2024
Q4 		$179K Buy
22,818
+2,545
+13% +$31K ﹤0.01% 2444
2024
Q3 		$267K Buy
20,273
+2,376
+13% +$30.1K ﹤0.01% 2224
2024
Q2 		$216K Buy
+17,897
New +$242K ﹤0.01% 2208

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's YMAB Position: Q3 2025 in Review

Mirae Asset Global ETFs Holdings sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 21,185 shares — an estimated $95.5K sold.

Mirae Asset Global ETFs Holdings first reported a position in YMAB in Q2 2024 and held it in 5 quarters. The position peaked at $267K in Q3 2024. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Mirae Asset Global ETFs Holdings reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mirae Asset Global ETFs Holdings sold 21,185 Y-mAbs Therapeutics shares in Q3 2025, an estimated $95.5K.
  • Mirae Asset Global ETFs Holdings first reported a position in Y-mAbs Therapeutics in Q2 2024 and held it in 5 quarters.
  • Mirae Asset Global ETFs Holdings's Y-mAbs Therapeutics position peaked at $267K in Q3 2024.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q3 2025, filed 14 Nov 2025.